医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Chlorella Industry Has Acquired FDA GRAS Certification for the Chlorella Powder Product, Unprecedented in Japan for the Exclusively Domestic Cultivation and Production of Chlorella

2022年06月06日 PM06:00
このエントリーをはてなブックマークに追加


 

TOKYO

Chlorella Industry Co., Ltd. (Minato-ku, Tokyo) has acquired FDA GRAS (Generally Recognized As Safe) certification for the chlorella powder product, unprecedented in Japan for the exclusively domestic cultivation and production of chlorella.

Chlorella is a plant-based food source, made up of about 60% protein, and comprised of a variety of vitamins and minerals, chlorophyll and omega-3 fatty acids. In addition, it contains vitamin B12, which is often deficient in vegans and vegetarians.

Having high contents of chlorophyll, Chlorella is used in green food coloring and the prevention of color fading. It is used in various foods such as health foods and supplements, bread and noodles, confectionery, probiotic beverages, smoothies, protein bars, green curry, etc.

About Chlorella Industry Co., Ltd.

Chlorella Industry Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Eiichiro Itanami) was founded in 1964 as the world’s first chlorella manufacturer. We carry out integrated production from cultivation to commercialization of the single-cell green alga Chlorella at the Kyushu Chikugo Factory in Chikugo City, Fukuoka, Japan. We have a wide range of chlorella product lineups including health foods, supplements, additives, agricultural and aquacultural materials. The company motto is “Health and Happiness for Humankind.”
https://www.chlorella.co.jp/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005438/en/

CONTACT

Chlorella Industry Co., Ltd.

Overseas Business Section

Masaki Iwasaka

Mail: masaki_iwasaka@chlorella.co.jp

同じカテゴリーの記事 

  • 佐賀大学とBostonGeneがEGFR陽性肺癌患者におけるICIの治療効果予測因子を特定するための新規バイオマーカー探索を目的とした研究を発表
  • KBI Biopharma任命Jean-Baptiste Agnus为首席商务官
  • First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
  • Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
  • LabVantage Celebrates Customer Success with Record Number of Software Deployments in FY 2024